CDC42 and coronary artery disorder: In conclusion, CDC42 negatively relates to lipid levels, inflammation, multivessel disease, and ACC/AHA type B2/C lesions, whose high expression after treatment is linked with lower TLF and MACE rates in DCB-treated SV-CAD patients.